Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

STATUS

Recruiting
End date

Mar 1, 2026
participants needed

35
sponsor

Dana-Farber Cancer Institute

Updated on 19 February 2024

See if I qualify

neutrophil count

carcinoma

prostatectomy

Summary

In this research study, is assessing the feasibility of using an MR-guided implantable microdevice to measure tumor response to chemotherapy and other clinically relevant drugs in participants that have prostate cancer and are scheduled for a radical prostatectomy.

The name of the study intervention involved in this study is:

Implantation of a MR-guided microdevice

Description

This research study is assessing the feasibility and safety of implanting and retrieving a 'microdevice' that releases up to 20 drugs directly within the prostate cancer lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against prostate cancer.

Participants will be identified with confirmed prostate cancer whose treatment plan includes surgery as a component of standard-of-care treatment.

The name of the study intervention involved in this study is:

Implantation of a MR-guided microdevice .
It is expected that about 35 people will take part in this research study; 5 in the Ex Vivo Cohort and 30 in Surgery Cohort.
Ex Vivo Cohort will undergo placement of microdevice in the prostate after its surgical removal.
Surgery Cohort will undergo percutaneous placement of several microdevices in a selected tumor prior to surgery.

This research study is a Pilot Study, which is the first-time investigators are examining this study intervention. The FDA (the U.S. Food and Drug Administration) has not approved the implantation of the microdevice for this specific disease, but usage of this has been approved for other uses.

Details

Condition	Malignant neoplasm of prostate, Prostatic disorder, Radical Prostatectomy
Age	22years - 100years
Treatment	Microdevice
Clinical Study Identifier	NCT04399876
Sponsor	Dana-Farber Cancer Institute
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Eligibility Criteria Ex Vivo Cohort
	Participants must have the ability to understand and the willingness to sign a written informed consent document
	Planned Radical Prostatectomy for Prostate Cancer
	Participants must be 22 years of age or older
	Eligibility Criteria for Surgical Cohort
	Participants must have the ability to understand and the willingness to sign a written informed consent document
	Participants must present with prostate cancer falling into an intermediate or high risk category to include features: Gleason score 3+4 or higher, greater than 3 biopsy cores positive and >50% of 1 core positive for carcinoma, and an MRI-visible lesion concerning for PCa in the region of the positive biopsy
	Participants must be 22 years of age or older
	Participants must be evaluated by a urologic oncologist who will determine the clinically appropriate treatment strategy based on clinical history and extent of disease
	Participants must be deemed medically stable to undergo both percutaneous procedures and standard-of-care surgical procedures by their treating surgeon
	Participants will undergo laboratory testing within 30 days prior to the procedure (or within 72 hours if there has been a change in the clinical status since the initial blood draw). Participants must have absolute neutrophil count 1,500/mcL, platelets 50,000/mcL, PT (INR) 0.8-1.2 and PTT within the normal range of the institution
	Participants must have undergone multi-parametric prostate MRI that both assesses the extent of disease and allows the research team to assess for study eligibility. This will have been done as part of the standard-of-care. Abnormal imaging will be correlated with the biopsy findings to maximize the likelihood of the device being put in the lesion. If the images are not adequate, the MRI scan will be repeated at BWH/DFCI, again as part of standard-of-care management
	The participant's case must be reviewed by representatives of urologic oncology and interventional radiology to assess the following factors
	Participant is clinically stable to undergo biopsy procedure(s) and surgical procedures
	Participant has sufficient volume of disease as shown by MRI to allow implantation of the microdevice
	A lesion can be selected where the microdevice is to be implanted that is a) amenable to percutaneous placement, and b) amenable to removal at the time of primary surgery -- Participants must be willing to undergo research-related genetic sequencing (somatic and germline) and data management, including the deposition of de-identified genetic sequencing data in NIH central data repositories
Exclusion Criteria
	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit the safety of a biopsy and/or surgery
	Uncorrectable bleeding or coagulation disorder known to cause increased risk with surgical or biopsy procedures (detailed below)

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

neutrophil count

carcinoma

prostatectomy

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer